Comparing MediciNova (NASDAQ:MNOV) & Fortress Biotech (NASDAQ:FBIO)

MediciNova (NASDAQ:MNOV) and Fortress Biotech (NASDAQ:FBIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, risk, dividends, institutional ownership and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for MediciNova and Fortress Biotech, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1	1	4	1	2.71
Fortress Biotech	1	1	2	0	2.25

MediciNova currently has a consensus price target of $7.75, suggesting a potential upside of 455.56%. Fortress Biotech has a consensus price target of $17.00, suggesting a potential upside of 804.26%. Given Fortress Biotech’s higher probable upside, analysts plainly believe Fortress Biotech is more favorable than MediciNova.

Institutional and Insider Ownership

9.9% of MediciNova shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 14.0% of MediciNova shares are held by company insiders. Comparatively, 28.5% of Fortress Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares MediciNova and Fortress Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,126.60%	-26.75%	-24.57%
Fortress Biotech	163.32%	83.47%	42.98%

Volatility and Risk

MediciNova has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.

Earnings & Valuation

This table compares MediciNova and Fortress Biotech”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410,000.00	167.47	-$12.00 million	($0.21)	-6.64
Fortress Biotech	$63.26 million	0.99	$6.82 million	$2.64	0.71

Fortress Biotech has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Summary

Fortress Biotech beats MediciNova on 11 of the 15 factors compared between the two stocks.

About MediciNova

MediciNova is a clinical-stage biopharmaceutical company that develops small-molecule drug candidates for neurological, pulmonary and other conditions. The company is based in La Jolla, California, and conducts research and clinical development through collaborations and studies in the United States and other countries. Its lead candidate, MN-166 (ibudilast), is being studied for several conditions, including amyotrophic lateral sclerosis, progressive multiple sclerosis and substance use disorders.

About Fortress Biotech

Fortress Biotech, Inc. is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiaries and affiliated companies. Its approach includes advancing drug candidates, acquiring or licensing development and commercialization rights, and building companies around selected products and programs. The company’s activities span areas including oncology, dermatology, rare diseases and immunology. Its portfolio has included marketed dermatology medicines such as Qbrexza, Amzeeq and Zilxi, as well as investigational therapies at various stages of development.